Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $26.44 Average Price Target from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has earned an average recommendation of "Hold" from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $26.44.

Several analysts have recently weighed in on PCRX shares. HC Wainwright lifted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC dropped their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Barclays boosted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th.

Pacira BioSciences Stock Up 0.3%

Shares of NASDAQ PCRX traded up $0.07 during trading hours on Friday, hitting $25.82. The stock had a trading volume of 615,215 shares, compared to its average volume of 973,747. The company has a market capitalization of $1.20 billion, a P/E ratio of -12.72 and a beta of 0.56. The firm's 50-day moving average price is $25.24 and its two-hundred day moving average price is $22.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.64.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC lifted its position in Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares during the period. Ancora Advisors LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at approximately $26,000. Caitlin John LLC grew its holdings in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Pacira BioSciences in the first quarter worth about $51,000. Finally, Brooklyn Investment Group increased its holdings in Pacira BioSciences by 372.2% during the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock worth $56,000 after purchasing an additional 1,764 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.